Maria Jasin, a pioneering molecular biologist whose groundbreaking work has reshaped our understanding of DNA repair mechanisms and their impact on cancer susceptibility, has been named the 2025 recipient of the prestigious Pearl Meister Greengard Prize. Awarded annually by Rockefeller University, this honor highlights outstanding women scientists who have made transformative contributions to biomedical research. Jasin’s fundamental discoveries in DNA double-strand break repair and gene editing have not only expanded scientific knowledge but also paved the way for novel therapeutic strategies in cancer treatment.
Jasin’s research has profoundly influenced the field of DNA repair, particularly by elucidating the process of homologous recombination—a precise cellular mechanism that cells use to repair potentially lethal double-strand breaks in DNA. Prior to her work, prevailing theories underestimated this pathway’s significance in mammalian cells. Through meticulous experimentation, Jasin demonstrated that homologous recombination is indeed a dominant and critical repair route, overturning conventional assumptions and providing new insights into genome stability and cellular resilience against DNA damage.
Central to her contributions is the detailed characterization of the tumor suppressor genes BRCA1 and BRCA2, famously linked to hereditary breast and ovarian cancers. Jasin’s lab showed that these genes orchestrate the repair of double-strand breaks through homologous recombination, thus preventing the accumulation of mutations that can drive malignant transformation. Loss or dysfunction of BRCA proteins severely compromises the cell’s ability to maintain genomic integrity, dramatically increasing cancer risk. Her findings not only illuminated the molecular basis of BRCA-related cancers but also identified vulnerabilities exploitable for targeted therapies.
The implications of her work extend beyond fundamental biology to clinical oncology. Jasin’s research uncovered how BRCA defects sensitize tumors to DNA-damaging agents and PARP inhibitors, advancing personalized medicine approaches that selectively kill cancer cells deficient in homologous recombination repair. This precision targeting has revolutionized treatment for patients with BRCA-mutated cancers, exemplifying how deep mechanistic understanding translates into therapeutic innovation.
In addition to defining DNA repair pathways, Jasin has been at the forefront of gene editing technologies. Her lab’s pioneering demonstration that inducing site-specific DNA breaks stimulates homologous recombination allowed her to perform some of the earliest controlled genome modifications in mammalian cells. This technique laid the bedrock for subsequent advances in gene editing, including CRISPR and other nuclease-based strategies, which promise corrective therapies for genetic disorders and novel cancer treatments.
Moreover, Jasin’s ongoing research delves into DNA repair dynamics across different developmental stages and cellular contexts, particularly within breast tissue. By examining how the efficiency and regulation of homologous recombination vary in breast cells during development and disease progression, her team aims to uncover new cancer vulnerabilities and resistance mechanisms. This nuanced understanding is crucial for devising next-generation therapeutic interventions that can overcome tumor heterogeneity and adaptive responses.
Her scientific trajectory reflects a commitment to unraveling the interplay between genome maintenance and cancer biology. With a Ph.D. from MIT and postdoctoral training at the University of Zürich and Stanford University, Jasin joined Memorial Sloan Kettering Cancer Center and the Weill Cornell Graduate School of Medical Sciences, where she continues to lead an internationally renowned laboratory. Her efforts have earned her membership in the National Academies of Sciences and Medicine and the American Academy of Arts and Sciences, signifying peer recognition of her monumental impact.
The Pearl Meister Greengard Prize, which Jasin will receive in a ceremony at Rockefeller University, was established by Nobel laureate Paul Greengard and his wife, Ursula von Rydingsvard, to honor exceptional women in science. Named after Greengard’s mother, this award celebrates not only scientific excellence but also the perseverance and creativity required to excel in a traditionally male-dominated field. Jasin’s selection underscores her role as an inspiring figure who has advanced both science and gender equity.
Michael W. Young, chair of the prize selection committee and a Rockefeller University professor, remarked that Jasin’s work “laid a foundation for developing gene editing as a tool for therapy.” By pioneering the concept that programmed chromosome breaks can stimulate precise genetic alterations, Jasin’s research initiated a paradigm shift that ripples across multiple biomedical disciplines, from developmental biology to regenerative medicine.
The ceremony honoring Jasin’s achievements will take place on September 16 at Rockefeller University and is open to the public with prior registration. It offers an opportunity for the scientific community and general audience alike to celebrate the monumental strides made in DNA repair research, gene editing, and cancer biology—fields that continue to save lives and push the boundaries of medicine.
Jasin’s career exemplifies how curiosity-driven fundamental research can unlock mechanisms critical for human health and disease prevention. Her elucidation of DNA repair pathways has fundamentally changed the landscape of cancer biology, providing the intellectual scaffolding for innovative diagnostics, prognostics, and treatments aimed at precision oncology. Moreover, her trailblazing gene-editing studies herald a new era in genetic medicine, with potential applications spanning inherited diseases to cancer.
Memorial Sloan Kettering Cancer Center, where Jasin conducts her research, remains at the forefront of integrating basic science and clinical application, fostering an environment where discoveries rapidly translate from bench to bedside. Jasin’s leadership in this milieu continues to inspire a new generation of scientists dedicated to decoding the complexities of genomic maintenance and cancer suppression.
Her accomplishments illustrate the power of multidisciplinary approaches bridging molecular biology, genetics, and clinical oncology to confront some of the most pressing challenges in medicine. As DNA repair research advances, building on the foundations laid by Jasin and her colleagues, it promises to deliver ever more refined and effective therapies, offering hope to millions affected by cancer and genetic disorders worldwide.
Subject of Research: DNA repair mechanisms, homologous recombination, BRCA gene function, cancer biology, gene editing technology
Article Title: Maria Jasin Awarded 2025 Pearl Meister Greengard Prize for Transformative Discoveries in DNA Repair and Gene Editing
News Publication Date: Not specified (2025 event announced)
Web References: https://www.rockefeller.edu/greengard-prize/
Image Credits: MSKCC
Keywords: Gene therapy, Breast cancer
